Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
AIP Emerges as a Potential Marker for Diabetic Kidney Risk
Clinician's RoundtableAIP Emerges as a Potential Marker for Diabetic Kidney Risk
Pediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
On the Frontlines of PsoriasisPediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
- advertisement
How GLP-1s Provide New Options to Manage Heart Disease
Medical Industry FeatureHow GLP-1s Provide New Options to Manage Heart Disease
Bridging the Gap: Lipid Management in ASCVD Patients with Diabetes to Reduce CV Risk
Medical Industry FeatureBridging the Gap: Lipid Management in ASCVD Patients with Diabetes to Reduce CV Risk
Rethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
Medical Industry FeatureRethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
- advertisement